Discovery of a Long-Chain Carbamoyl Aminocarnitine Derivative, a Reversible Carnitine Palmitoyltransferase Inhibitor with Antiketotic and Antidiabetic Activity
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The synthesis and pharmacological activity of reversible CPT I inhibitors as potential antiketotic and antidiabetic drugs are reported. Such inhibitors constitute a series of enantiomerically pure aminocarnitine derivatives having the general formula (CH3)3N+CH2CH(ZR)CH2COO- (with Z = ureido, carbamate, sulfonamide, and sulfamide moieties; R = C7-C14 linear alkyl chains). A primary pharmacological screening based on the evaluation of CPT I activity in intact rat liver (L-CPT I) mitochondria revealed the best activity for the (R) forms of ureidic derivative 17 (ZR = NHCONHR, R = C14), sulfonamidic derivative 7 (ZR = NHSO2R, R = C12), and sulfamidic derivative 9 (ZR = NHSO2NHR, R = C11). The IC50 values are 1.1, 0.7, and 0.8 microM, respectively. For the carbamic derivative 11 (ZR = NHCOOR, R = C8), an IC50 of 9.5 microM was observed. In addition, an extraordinarily high selectivity toward the liver isoform with respect to the heart isoform (muscle-CPT I identical with M-CPT I) was found for the ureidic compound 17 (IC50(M-CPT I) vs IC50(L-CPTI) = 39.4), as well as for other ureidic or carbamic compounds. Diabetic db/db mice treated orally with 17 and 7 for 45 days at a dose of 50 mg/kg twice a day showed a good reduction of serum glucose levels with respect to the untreated db/db mice (p < 0.01). In addition, 17 showed antiketotic activity in normal fasted rats. 17 has been selected for development as a potential antiketotic and antidiabetic drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Mitochondrial Carnitine Palmitoyltransferase System — From Concept to Molecular Analysis
McGarry, J. D., & Brown, N. F. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00001.x · Cited by 1,616
Cited by
CPT1A-mediated Fat Oxidation, Mechanisms, and Therapeutic Potential
Schlaepfer, I. R., & Joshi, M. (2020) · Endocrinology · doi:10.1210/endocr/bqz046 · Cited by 732
Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer
Qu, Q., Zeng, F., Liu, X., Wang, Q. J., & Deng, F. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.132 · Cited by 545
Energy metabolism in health and diseases
Liu, H., Wang, S., Wang, J., Guo, X., Song, Y., Fu, K., Gao, Z., Liu, D., He, W., & Yang, L.-L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02141-x · Cited by 399
A brain-liver circuit regulates glucose homeostasis
Pocai, A., Obici, S., Schwartz, G. J., & Rossetti, L. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2004.11.001 · Cited by 392
“ICV delivery of CPT1 inhibitors For the pancreatic-insulin clamp studies, ST1326 [(R)-N-(tetradecylcarbamoyl)-aminocarnitine] and ST1340 (the inactive stereo-isomer of ST1326) [(S)-N-(tetradecylcarbamoyl)-aminocarnitine] (Sigma-Tau Department of Metabolism & Endocrinology, Sigma Tau Pharmaceutical Industries, Pomezia,…”
MethodObesity-related derangements in metabolic regulation
Muoio, D. M., & Newgard, C. B. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142512 · Cited by 345
Lipid metabolic enzymes: emerging drug targets for the treatment of obesity
Shi, Y., & Burn, P. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1469 · Cited by 333
Targeting mitochondrial metabolism for precision medicine in cancer
Sainero-Alcolado, L., Liaño-Pons, J., Ruiz-Pérez, M. V., & Arsenian-Henriksson, M. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-01022-y · Cited by 322
Regulatory enzymes of mitochondrial β‐oxidation as targets for treatment of the metabolic syndrome
Schreurs, M., Kuipers, F., & Van Der Leij, F. R. (2010) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00642.x · Cited by 296
Mitochondrial fatty acid oxidation in obesity
Serra, D., Mera, P., Malandrino, M. I., Mir, J. F., & Herrero, L. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4875 · Cited by 246
“Alternatively, it has been reported that the admistration of CPT1 inhibitors reduces gluconeogenesis and improves glucose homeostasis, although chronic treatments on HFD-treated mice caused hepatic steatosis (28, 53).”
Mitochondrial CPT1A: Insights into structure, function, and basis for drug development
Liang, K. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1160440 · Cited by 156
“An amino-carnitine analog called ST1326 (oral formulationTeglicar) was initially created for diabetic ketoacidosis (Giannessi et al., 2003).”
BackgroundMuoio, D. M., & Koves, T. R. (2007) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h07-083 · Cited by 129
Conti, R., Mannucci, E., Pessotto, P., Tassoni, E., Carminati, P., Giannessi, F., & Arduini, A. (2011) · Diabetes · doi:10.2337/db10-0346 · Cited by 98
Self-citation
Metadata
- Authors
- Giannessi, F., Pessotto, P., Tassoni, E., Chiodi, P., Conti, R., De Angelis, F., Dell'Uomo, N., Catini, R., Deias, R., Tinti, M. O., Carminati, P., & Arduini, A.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2002-12-17
- Volume
- 46
- Issue
- 2
- Pages
- 303-309
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2040499509
- Cited by
- 73
- References
- 1
- FWCI
- 1.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.